459
NEUROLOGIE3418043010757101158205267310370429450493
PRO856804301074591154
PRAXI1031804301074591148201221
/12988043010731
Neurol.1374804301075593139165209227243
praxi.1633804301074672114152170186
2024;25(1):53-561836804301074487128168183227271293333350365409451478521564
/24458043010732
www.neurologiepropraxi.cz460880430107651332012142633073553814284484965465656086586857327828098518919109269661005
561838026012657115
PŘEHLEDOVÉ341207012660124182256312369444520587645
ČLÁNKY1008207012660115187259327395
Ocrelizumab34136501063873109141173191223264318358394
–751365010645
co81136501063372
víme,89836501063754108140157
co107036501063271
můžeme115736501065192124156211242
zlepšit14153650106316294129163180212
nyní164336501063976118135
a1794365010638
co184736501063372
v1934365010637
budoucnu198636501063475115156197232273314
on3405540833775
in4285540831452
multiple4935540835794109131146185201235
sclerosis741554083265873107128165191206232
patients986554083387192107142179201228
treated1227554083214276108129163202
with1441554083516688126
rituximab158055408320365895126142199231270
is18625540831541
not1915554083387697
predictive340654083396094134149181205220252287
of6406540833756
a70965408332
risk75465408320366292
of8596540833756
relapse928654083215571103142168203
or11446540833859
clinical121665408331476299114146179194
progression.1423654083396198137158192219246260298337350
J178665408324
Neurol.18216540834273109129164179192
2022;269(10):5443-5453.3407540833468101136148183217251270302333351363399434471503525559594627660673
8.3408530853652
Hartung405854083447697122160198237
HP,655854083447984
Berger752854083357091129164185
T,9508540833241
Bermel1004854083357092150185200
R,12178540833650
et12798540833457
al.1348854083324760
Shorter14218540833370109130155188209
infusion1643854083155372110136151189227
time1883854083223795130
of3409540833757
ocrelizumab:411954083377091125141156185223281313353365
Results791954083357097134149172199
from1005954083184078136
the1155954083226095
randomized,1265954083215492131169227242271305345358
double‑blind16379540833876114154170204228268284299336375
ENSEMBLE34010540833275106138191226257289
PLUS64010540833565106137
substudy7881054083266299125147184222252
in105210540831451
patients11141054083387091105139176196223
with13481054083506486123
relapsing‑remitting1482105408320536899137163177213251272293326382397418442456493530
multiple34011540835795110133148187203238
sclerosis.5931154083265874109130167194209235248
Mult85711540835389104124
Scler9941154083316075105126
Relat11321154083346579115136
Disord.12801154083446083118139173187
2020;46:102492.148211540833468101135148183219231261293325357390424436
9.34012530853649
Hauser40512540834476114140175197
SL,6171254083336478
Bar‑Or7101254083366990110160181
A,90712540834155
Comi97812540834077135150
G,114412540834457
et121712540833456
al.12891254083324760
Ocrelizumab136512540834780101135151166195233291323362
versus17431254083326687115152178
Interferon193712540831553340135408322557698132153190228
Beta-1a5811354083357092125147178206
in80013540831552
Relapsing8651354083367086118157183198236275
Multiple115313540835491107129144183199233
Sclerosis.13991354083336580115136173199214240254
N1666135408343
Engl171913540833167102117
J1846135408324
Med.188113540835283119132
2017;376(3):221-234.34014540833468100129139174206238257291308320355390421440471506541554
10.3401553085356883
Hauser43515540834375112137172192
SL,6391554083326376
Bar‑Or7271554083356788107156177
A,91615540834054
Weber98215540835789127162183
MS,11771554083548698
et128715540833455
al.13551554083314658
Association14251554083416894131163178209230245282319
of175715540833655
Higher18241554083445896133168188
Ocrelizumab34016540834780101135151165195233291323362
Exposure71616540833265104143170207228262
With9921654083577396134
Reduced113916540833671110148180213253
Disability14051654083466187120160175190205228262
Progression16801654083355693133154188215241256294332
in34017540831553
Multiple40817540835592108130145185200235
Sclerosis.6591754083326580115136173200215241254
Neurol-Neuroimmunol92917540834373109130165180201246276312333368383438494530567603618
Neuroinflamma‑156017540834273109129164179216232248283339395431452
tion.3401854083203571108447185408312
2023;10(2):e200094.47518540833468101135147177208228262280292326361395431467502538550
11.3401953085366678
He43319540834479
A,52719540834155
Merkel59719540835490111141175191
B,80319540833548
Brown8661954083355794145184
JWL,106419540832583115129
et120819540833456
al.12791954083324760
Timing135419540833349107122160199
of156819540833757
high‑efficacy16391954083385392130152189207225243275308340373
therapy3402054083226095116149188219
for5752054083195678
multiple66820540835895111133148188203238
sclerosis:9222054083265874108130167194209235247
a1185205408332
retrospective1232205408321557799136163202237270294309342376
observational162420540833777103138160194227249264302341373388
cohort34021540833168107145167191
study.5472154083264987126158168
Lancet72821540832964101130159181
Neurol.92121540834373109130165180193
2020;19(4):307-316.112621540833468101135148178208228261278290325360392411443474505519
12.3402253085366884
Kappos43922540833568108147186213
L,66722540833245
Wolinsky72822540835794110125163189219253
JS,9962254083255669
Giovannoni10812254083445997129162200238276315330
G,142622540834457
et149922540833456
al.15712254083324760
Contribution164722540833977115136158174213251273289327365
of34023540833757
Relapse‑Independent4112354083357086118157184219242258296336370410445483522557595617
Progression10422354083355693133154188215241256294332
vs138923540833158
Relapse‑Associated14612354083367186119158184219243284312338377409424456478512551
Worsening21405540835794115143178216231269308
to24635540832259
Overall25375540834780115136169184199
Confirmed27525540833976115132149170229264303
Disability3071554083456087120159174190205227261
Accumulation33475540834172103141199237252284306321359398
in37605540831452
Typical21406540833360100116148181196
Relapsing2350654083357085118157184198236275
Multiple26396540835492108130145184200235
Sclerosis2888654083326480115136173200215241
in31426540831553
a320865408332
Pooled32546540833572110126161201
Analysis34686540834179112127159186201227
of37086540833757
2377865408335
Randomized21407540833568105144182240254283317356
Clinical2509754083405469107122153186201
Trials.272375408332496496111137150
Jama28847540832459115150
Neurol.30457540834272108128163178191
2020;77(9):1132-1140.32467540833468100134147179213230262280291321348378410430461488519554567
13.2140853085366883
Kempen22368540833569127166201239
ZL24888540833870
van,25718540833164102115
Hogenboom26998540834482121156194233272311369
L,30818540833145
Killestein313985408335516681116143166200215253
J.34058540832436
Stable3454854083335486125141176
multiple364385408357951101331482140954083395489
sclerosis2242954083265873108129166192207233
patients2488954083387193108142180201229
on27309540833775
anti‑CD202818954083326991106128170216248282
therapy3113954083215994115148187218
should33449540832663101139154193
go35509540833876
on36399540833775
extended3727954083346521401054083225593133167207
interval23621054083155374108129164197212
dosing:259010540833876103117155194207
NO.281210540834593104
Mult293210540835389104124
Scler30691054083316075105126
J.320710540832437
2022;28(5):693-695.325910540833468101136148183217236269288300335369402424461495529541
14.21401153085367085
Kister22471154083355279102137158
I,242611540831528
Oh247511540834887
C,258311540834054
Douglas265711540834686124164180212239
EA,29171154083337791
et302911540833457
al.31071154083324861
No318911540834584
Increase32941154083155486108143175202238
in355311540831453
Symptoms362711540833363122162214012540832261121148
Toward231012540833369121155177217
the25491254083226198
End266812540833473113
of280312540833858
the28831254083226298
Ocrelizumab300312540834882104139156172202241301335378
Infusion34061254083165779121151169210252
Cycle368412540834172107214013540831554
in222213540831557
Patients23071354083367297115154196221252
With258713540835978104146
Multiple276113540835798117143161204223262
Sclerosis.30511354083336988127151192223241270287
Neurol:336613540834478118142180198213
Clin36031354083395674114
Pr.37411354083345771
2023;13(5):e200185.214014540833470105142156188220240276296310347383419458492525561575
15.21401553085356984
Montalban223815540835492130152184200239272310
X,256115540833851
Matthews262615540835386108132170205256283
PM,292215540833588102
Simpson303715540833247104143170208247
A,329715540834055
et336515540833456
al.34351554083314760
Real‐world350815540833570102117140191228250266305
evaluation21401654083336698114151183205220258296
of245016540833656
ocrelizumab25191654083376991125140155184222280312351
in288316540831552
multiple294916540835694109131147186202236
sclerosis:31991654083255773108129166192207233246
A3458165408341
systematic35121654083265885108142199232253269301
review.21401754083215588105140192204
Ann236117540833875112
Clin24871754083385369106
Transl26071754083314882120144159
Neurol.278017540834273110132167183197
2023;10(3):302-311.299317540833469103138150181213233268286298334369403424457489517527
16.21401853085367189
Pfeuffer22511854083355894134155179216239
S,251218540833347
Rolfes25811854083357694115152181
L,278318540833248
Ingwersen28521854083155596150186210239276316
J,319018540832438
et325018540833458
al.33301854083325065
Effect34161854083335477114149175
of361318540833758
Previous3693185408335589421401954083324990130158
Disease‑Modifying23181954083466392129163191228254312352394411433469487527568
Therapy290619540833374111135170211244
on317119540833778
Treatment32691954083325288122146206243283307
Effectiveness35961954083335377114149175192214020540833167106143171199
for23552054083195881
Patients24522054083356891108144184207236
Treated27042054083335187120143178219
With29402054083567498138
Ocrelizumab.309420540834781103139156173203243302335376390
Neurology350020540834581120143181199238279313
Neuroimmunol214021540834481121144183201260320359399439457
Neuroinflammation.261421540834582121144183201241261281315375435469493510550590605
2023;10(3):e200104.323621540833470105142155187220242277296310347383419457490524562576
17.21402253085367081
Song223922540833273113155
A,241222540834157
Hendricks248822540834481121163186204238270301
R,280722540833652
Chung287722540834080120160201
S,309722540833247
et316322540833458
al.32402254083314964
Immunogenicity332322540831474134174214254296333371386418433456489
with21402354083516689127
Repeated228123540833671110146177199233272
Dosing256823540834584111126163202
of278523540833757
Ocrelizumab285623540834780101135151166195233291323362
in323323540831553
Patients33002354083356789104139177199226
with35412354083506689127
Multiple368223540835593108394055408322377692127
Sclerosis4087554083326580115136173200215241
(P2.087)4348554083195488100136171204223
Neurology45925540834479117138175191229269301
Apr49135540834180102
2016,50355540833468100131144
8651995540833470
(165289554083185081
Supplement)5390554083337010914916519939406540835893132153173
P2.087.4133654083367082118154187193
Avalilable43476540834172105121136152184224240275
form:4643654083185678137150
htps://n.neurology.org/content/86/16_Supplement/P2.087.481365408338601001271391661872242372773123503714094254645045365465856076456717017387773940754083225593115142177212237270301338373410450489505540598633671692720756790803838873906912
18.3940853085377289
Toorop40518540833469109132171212
AA,42858540834388103
Lierop4410854083324985107146187
ZYGJ46198540833978122149
van,47918540833267106120
Strijbis493385408333567895111152168196
EMM,51518540833391148162
et53368540833558
al.5416854083334963
The55018540833475111
wearing‑off39409540835084116136152190230254294315337
phenomenon42939540833877113152191250286325365404
of47129540833758
ocrelizumab4785954083377093128144160190230288321362
in51629540831453
patients5230954083397395112147186209238
with5483954083506790129
multiple394010540835796113137154194211248
sclerosis.42061054083265976112135174202218246261
Mult448510540835390107129
Scler46291054083316278109131
Relat,47761054083346582119141155
DiS.49471054083436092107
2022;57:103364.507210540833470104140154190225237268301335370405443457
19.39401153085367085
Torres40411154083336891114150178
J,423511540832438
Roodselaar428911540833675115156184220237271305327
J,463311540832437
Sealey468711540833268102119155188
M,489111540835569
et497711540833457
al.50511154083324863
Distribution51301154083456290114137154195234258275314354
and550111540833171111
Efficacy3940125408333537693126161194229
of418712540833758
Ofatumumab426312540834769103126166225264323357398
and467812540833272112
Ocrelizumab480812540834781103139156172203242302335376
in520212540831454
Humanized527412540834483142176215232262298338
CD20394013540834087120156
Mice411213540835471104139
Following42671354083327188105144196213253293
Subcutaneous457613540833271111145184208242282318358397425
and501713540833271111
Intravenous51441354083155477100134167203242282321349
Administration.550913540834080394014540835774113130157182205239262279318358373
Front43311454083315187125147
Immunol.449314540831572129167205242258273
2022;13:814064.478414540833470104140154185217229266299331369406444458
20.39401553085367490
Vermersch40541554083367093153190213242276316
P,439315540833541
Oreja‐Guevara445815540834770106123157181229269306340374397432
C,491315540834055
Siva49911554083334983118
A,513215540834257
et521315540833458
al.52941554083324964
Efficacy5381155408333537794128162196231
and394016540833170110
safety40651654083266080115139173
of425416540833657
ocrelizumab43261654083377093128144160190229288321361
in470216540831553
patients47711654083387294111146185208236
with50221654083516791130
relapsing‐remitting5167165408320557210514517218822726729031334840642339401754083224764103143
multiple409817540835796113136153193210246
sclerosis43601754083265976112134173201217244
with46191754083516891131
suboptimal476517540832665105145186209225284318334
response51151754083205684124164203231267
to539817540832159
prior54731754083386178117140
disease‐modifying39401854083385582119152180216241301341381398419455472511551
therapies:45071854083226298121155195212249277291
A4814185408340
primary48701854083396279138172194230
analysis511618540833271105121155183199227
from53591854083184280140
the55151854083216197
phase394019540833979112140177
34138195408334
b4187195408338
CASTING424719540833984119155172219265
single‐arm,45331954083264282122139175198230252310323
open‐label487419540833777112150173189221261296312
trial.5204195408322435991106119
Eur53421954083316686
J5443195408324
Neu‑548219540834373110131
rol.3940205408320557083
2022;29(3):790-801.403820540833468101136148183217236270287299332366402425461497528538
21.39402153085367082
Zecca404021540833871104135168
C,422621540834053
Bovis429721540833574106122148
F,446321540833238
Novi451921540834583115131
G,466821540834457
et474421540833456
al.48182154083324760
Treatment48962154083335084116138196231269291
of520521540833756
multiple528021540835794110132147187202237
sclerosis55362154083265839402254083155071108135150176
with41302254083506688126
rituximab:4270225408321365997128144201234273285
a4569225408332
multicentric461422540835895111133148180214252274295311343
Italian–Swiss4970225408315377086100132171207238288303330356
experience.53402254083346510514016217721225039402354083316577
Mult403323540835389104124
Scler41702354083316075105126
J.430823540832437
2019;26(12):1519-1531.436023540833468100130143178212231262292310322352382413443467497527560591601
3.4.66876920314143218346502580
10.131076920314143281354
2024172676920314144290435582
ÚSTÍ40379920314174329486577
NAD106079920314176360552
LABEM169179920314132321493648883
4.149553940937288394
dny23963060503244482687
praktické10056306050324440361584210011118129615261732
neurologie49167360503240452690849108211961430166617801993
VÍCE32267901019067101162220
INFORMACÍ34757901019032107164238306405477537570
NA40747901019074145
www.kongresneurologie.cz32248055019610220831434841949056764369476682189896910461097117112101282135713971468150615581619